Back to news
News
Press Release
Mon. 6 January

4th Letter to Shareholders

Share on

Discover OPM’s 4th Letter to Shareholders!

Focus on

  • ANIMUS Program
  • OPM-101: promising clinical development
  • The immuno-oncology and IBD market
  • Interviews with our independent Board members
  • Latest news and details of the OPM-201 rights takeover
Read more

Read the others news

OPM reacquires rights to its OPM-201 program from Servier after a positive Phase I trial in healthy volunteers
News
Press Release
Fri. 20 December

OPM reacquires rights to its OPM-201 program from Servier after a positive Phase I trial in healthy volunteers

Read more
OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101
News
Press Release
Tue. 22 October

OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101

Read more
OPM announces poster presentation on OPM-101
News
Press Release
Tue. 15 October

OPM announces poster presentation on OPM-101

Read more
Read all news

Subscribe to the OPM newsletter

Subscribe to the newsletter to not miss any news!